Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults

NCT00845507 on ClinicalTrials.gov · last registry update 2018-04-20

Finished July 2015, after enrolling 54 people. Primary outcome, as filed: Change in Weight From Baseline to Endpoint. exenatide is approved in the US, but not for obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: University of Cincinnati
Sponsor type: Other
Enrollment: 54
Started: 2008-12
Primary completion: 2015-07 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Weight From Baseline to Endpoint.

Conditions studied

Weight Gain

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.